Latest News for: olema
Edit
Caledonian Record
03 Jul 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Edit
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Olema Pharmaceuticals Inc)
Public Technologies 02 Jul 2026
Edit
Statement of Changes in Beneficial Ownership (Form 4) (Olema Pharmaceuticals Inc)
Public Technologies 23 Jun 2026
) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) ... See Instruction 10. UNITED STATES SECURITIES AND EXCHANGE COMMISSION ... 0.5 ... 2 ... Olema Pharmaceuticals, Inc ... Olema Pharmaceuticals Inc.
Edit
Proxy Results (Form 8-K) (Olema Pharmaceuticals Inc)
Public Technologies 23 Jun 2026
) Item 5.07 Submission of Matters to a Vote of Security Holders. On June 17, 2026, Olema Pharmaceuticals, Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting") ... Nominees. For ... Olema Pharmaceuticals Inc.
Edit
The Best Seaside Escapes for a Weekend Away From San Francisco
New York Observer 28 May 2026
The furthest south you can go within that time frame is Big Sur, one of California’s most sought-after destinations for road trippers ... Big Sur ... Big Sur ... Olema House is a 24-room boutique hotel situated on the outskirts of Point Reyes National Seashore ... .
Edit
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer (Form 8-K) (Olema Pharmaceuticals Inc)
Public Technologies 26 May 2026
Edit
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in ...
Nasdaq Globe Newswire 26 May 2026
Edit
Hastings Tribune
22 May 2026
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a
OP-3136 monotherapy was well-tolerated with no dose-limiting ...
Edit
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting (Olema Pharmaceuticals Inc)
Public Technologies 21 May 2026
Edit
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting (Form 8-K) (Olema Pharmaceuticals Inc)
Public Technologies 21 May 2026
Edit
Olema Oncology to Participate in Upcoming Investor Conferences (Olema Pharmaceuticals Inc)
Public Technologies 19 May 2026
SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq ... Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts ... Olema Oncology. media@olema.com.
Edit
Hastings Tribune
12 May 2026
Olema Oncology Reports First Quarter 2026 Financial and Operating Results
Edit
Olema Oncology Reports First Quarter 2026 Financial and Operating Results (Form 8-K) (Olema Pharmaceuticals Inc)
Public Technologies 12 May 2026
Edit
Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) (Olema Pharmaceuticals Inc)
Public Technologies 12 May 2026
Olema is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of next-generation targeted therapies for breast cancer and beyond ... Olema Pharmaceuticals Inc.
- 1
- 2
- Next page »